Design Therapeutics, Inc. Increase (Decrease) in Accounts Payable and Other Operating Liabilities
Design Therapeutics, Inc. (DSGN) reported Increase (Decrease) in Accounts Payable and Other Operating Liabilities of -$1.56 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities · last filed 2026-08-03
- Design Therapeutics, Inc. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2026-06-30 was $955.00K, a 76.20% increase year-over-year.
- Design Therapeutics, Inc. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2026-03-31 was -$2.51M.
- Design Therapeutics, Inc. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2025-12-31 was $1.84M, a 82.72% increase year-over-year.
- Design Therapeutics, Inc. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2025-09-30 was $2.40M, a 136.48% increase year-over-year.
- Design Therapeutics, Inc. increase (decrease) in accounts payable and other operating liabilities for fiscal 2025 was $4.49M.
- Design Therapeutics, Inc. increase (decrease) in accounts payable and other operating liabilities for fiscal 2024 was -$1.22M.
- Design Therapeutics, Inc. increase (decrease) in accounts payable and other operating liabilities for fiscal 2023 was -$1.25M, a 123.07% decline from fiscal 2022.
- Design Therapeutics, Inc. increase (decrease) in accounts payable and other operating liabilities for fiscal 2022 was $5.40M, a 123.33% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 3 month | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 6 month | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 9 month | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 9 month as first filed | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $955.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$1.56M 10-Q · filed 2026-08-03 | $284.00K derived: sum of 3 quarters · filed 2026-08-03 | $2.69M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2026-03-31 | -$2.51M 10-Q · filed 2026-04-28 | -$671.00K derived: sum of 2 quarters · filed 2026-04-28 | $1.73M derived: sum of 3 quarters · filed 2026-04-28 | $2.28M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-12-31 | $1.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $4.25M derived: sum of 2 quarters · filed 2026-03-09 | $4.79M derived: sum of 3 quarters · filed 2026-08-03 | $4.49M 10-K · filed 2026-03-09 | |
| 2025-09-30 | $2.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $2.95M derived: sum of 2 quarters · filed 2026-08-03 | $2.65M 10-Q · filed 2025-11-05 | $3.65M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-06-30 | $542.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $241.00K 10-Q · filed 2026-08-03 | $1.25M derived: sum of 3 quarters · filed 2026-08-03 | $2.27M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-03-31 | -$301.00K 10-Q · filed 2026-04-28 | $706.00K derived: sum of 2 quarters · filed 2026-04-28 | $1.72M derived: sum of 3 quarters · filed 2026-04-28 | $1.00M derived: sum of 4 quarters · filed 2026-04-28 | |
| 2024-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $2.02M derived: sum of 2 quarters · filed 2026-03-09 | $1.30M derived: sum of 3 quarters · filed 2026-03-09 | -$1.22M 10-K · filed 2026-03-09 | |
| 2024-09-30 | $1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $297.00K derived: sum of 2 quarters · filed 2025-11-05 | -$2.23M 10-Q · filed 2025-11-05 | -$5.04M derived: sum of 4 quarters · filed 2025-11-05 | |
| 2024-06-30 | -$720.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$3.24M 10-Q · filed 2025-08-07 | -$6.05M derived: sum of 3 quarters · filed 2025-08-07 | -$5.81M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | -$2.52M 10-Q · filed 2025-05-07 | -$5.33M derived: sum of 2 quarters · filed 2025-05-07 | -$5.09M derived: sum of 3 quarters · filed 2025-05-07 | -$2.02M derived: sum of 4 quarters · filed 2025-05-07 | |
| 2023-12-31 | -$2.81M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$2.57M derived: sum of 2 quarters · filed 2025-03-10 | $499.00K derived: sum of 3 quarters · filed 2025-03-10 | -$1.25M 10-K · filed 2025-03-10 | |
| 2023-09-30 | $239.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $3.31M derived: sum of 2 quarters · filed 2024-11-07 | $1.56M 10-Q · filed 2024-11-07 | $1.99M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $3.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $1.32M 10-Q · filed 2024-08-05 | $1.75M derived: sum of 3 quarters · filed 2024-08-05 | $4.91M derived: sum of 4 quarters · filed 2024-08-05 | |
| 2023-03-31 | -$1.75M 10-Q · filed 2024-05-08 | -$1.32M derived: sum of 2 quarters · filed 2024-05-08 | $1.84M derived: sum of 3 quarters · filed 2024-05-08 | $3.44M derived: sum of 4 quarters · filed 2024-05-08 | |
| 2022-12-31 | $423.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $3.59M derived: sum of 2 quarters · filed 2024-03-19 | $5.18M derived: sum of 3 quarters · filed 2024-03-19 | $5.40M 10-K · filed 2024-03-19 | |
| 2022-09-30 | $3.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $4.76M derived: sum of 2 quarters · filed 2023-11-13 | $4.98M 10-Q · filed 2023-11-13 | $4.97M 10-Q · filed 2022-11-03 | $4.95M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $1.81M 10-Q · filed 2023-08-14 | $1.79M derived: sum of 3 quarters · filed 2023-08-14 | $3.16M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $215.00K 10-Q · filed 2023-05-09 | $189.00K derived: sum of 2 quarters · filed 2023-05-09 | $1.56M derived: sum of 3 quarters · filed 2023-05-09 | $1.26M derived: sum of 4 quarters · filed 2023-05-09 | |
| 2021-12-31 | -$26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $1.35M derived: sum of 2 quarters · filed 2023-03-14 | $1.04M derived: sum of 3 quarters · filed 2023-03-14 | $2.42M 10-K · filed 2023-03-14 | |
| 2021-09-30 | $1.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $1.07M derived: sum of 2 quarters · filed 2022-11-03 | $2.44M 10-Q · filed 2022-11-03 | $3.17M derived: sum of 4 quarters · filed 2022-11-03 | |
| 2021-06-30 | -$306.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $1.07M 10-Q · filed 2022-08-08 | $1.79M derived: sum of 3 quarters · filed 2022-08-08 | ||
| 2021-03-31 | $1.38M 10-Q · filed 2022-05-09 | $2.10M derived: sum of 2 quarters · filed 2022-05-09 | |||
| 2020-12-31 | $722.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $1.43M 10-K · filed 2022-03-10 | |||
| 2020-09-30 | $708.00K 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |